Sycrest is a sublingual tablet marketed as Sycrest in Europe, and as Saphris in other markets worldwide.
Sycrest is an antipsychotic that differs structurally from currently available medications to treat bipolar disorder and has a functional activity profile that is different, the company said.
Sycrest has been granted marketing authorizations in Europe for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Bipolar I disorder, a long-term condition, characterized by alternations between two poles of extreme moods, mania and depression, or a combination of both.